A Study of LY2944876 in Healthy Japanese and Non-Japanese Participants

Inclusion Criteria: * Healthy males or female participants * Are first generation Japanese participants (Part A) or non-Japanese participants (Part B) * Have a body mass index (BMI) of 18.5 to 30 kilogram per meter square (kg/m\^2), inclusive, for Part A and a BMI of 25 to 40 kg/m\^2, inclusive, for Part B at screening * Have normal blood pressure and heart rate (after approximately 5 minutes supine and approximately 2 minutes standing) as determined by the investigator at screening Exclusion Criteria: * Have known allergies to LY2944876, related compounds or any components of the formulation, or history of significant atopy * Have an abnormality in the 12-lead electrocardiogram (ECG) at screening and/or baseline that, in the opinion of the investigator, increases the risks associated with participating in the study * Have significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data * Have a history of acute or chronic pancreatitis or elevation in serum lipase and/or amylase greater than 2 times the upper limit of normal (ULN) at screening and/or baseline * Have known or ongoing psychiatric disorders considered clinically significant in the opinion of the investigator * Have undergone any form of bariatric surgery * Have fasting blood glucose levels greater than or equal to (≥) 7 millimoles per liter (mmol/L) \[≥126 milligrams per deciliter (mg/dL)\] at screening * Have fasting triglycerides levels ≥300 mg/dL (3.4 mmol/L) at screening * Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or an alanine transaminase (ALT) or aspartate aminotransferase (AST) levels greater than (\>) 2.5 times the ULN at screening and/or baseline * Have used or intend to use medications that promote weight loss, within 3 months prior to screening, for the duration of the study